 | |
| Clinical data | |
|---|---|
| Other names | (+)-4-(dimethylamino)-α,2-dimethylphenethylamine |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H20N2 |
| Molar mass | 192.306 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Amiflamine (FLA-336) is areversible inhibitor ofmonoamine oxidase A (MAO-A), thereby being aRIMA, and, to a lesser extent,semicarbazide-sensitive amine oxidase (SSAO), as well as aserotonin releasing agent (SRA).[1][2][3][4] It is aderivative of thephenethylamine andamphetaminechemical classes.[1] The (+)-enantiomer is the activestereoisomer.[2]
Amiflamine shows preference for inhibiting MAO-A inserotonergic relative tonoradrenergic anddopaminergicneurons.[5][6] In other words, at low doses, it can be used to selectively inhibit MAO-A enzymes in serotonin cells, whereas at higher doses it loses its selectivity.[5][6] This property is attributed to amiflamine's higheraffinity for theserotonin transporter over thenorepinephrine anddopamine transporters, as transporter-mediated carriage is required for amiflamine to enter monoaminergic neurons.[6]
